This article has Open Peer Review reports available.
46,XX ovotesticular disorder in a Mexican patient with Beckwith–Wiedemann syndrome: a case report
© Macias-Gomez et al.; licensee BioMed Central Ltd. 2012
Received: 2 February 2012
Accepted: 2 July 2012
Published: 13 September 2012
Beckwith–Wiedemann syndrome is an overgrowth syndrome that is characterized by hypoglycemia at birth, coarse face, hemihypertrophy and an increased risk to develop embryonal tumors. In approximately 15% of patients, the inheritance is autosomal dominant with variable expressivity and incomplete penetrance, whereas the remainder of Beckwith–Wiedemann syndrome cases are sporadic. Beckwith–Wiedemann syndrome molecular etiologies are complex and involve the two imprinting centers 1 (IC1) and 2 (IC2) of 11p15 region. This case report describes, for the first time, the unusual association of ovotesticular disorder in a patient from Morelia, Mexico with Wiedemann-Beckwith syndrome.
We report the case of a Mexican six-year-old girl with Beckwith–Wiedemann Syndrome, ambiguous genitalia, and bilateral ovotestes. She has a 46,XX karyotype without evidence of Y-chromosome sequences detected by fluorescence in situ hybridization with both SRY and wcp-Y probes.
Although a random association between these two conditions cannot be excluded, future analysis of this patient with Beckwith–Wiedemann syndrome and 46,XX ovotesticular disorder may lead to new insights into these complex pathologies. We speculate that a possible misregulation in the imprinted genes network has a fundamental role in the coexistence of these two disorders.
Beckwith–Wiedemann syndrome (BWS; Mendelian Inheritance in Man [MIM] #130650), the most common overgrowth syndrome, has been described worldwide with an incidence of 1 in 12,000 to 13,700 live births, and is characterized by macrosomia, macroglossia, visceromegaly, abdominal wall defects, hemihyperplasia, renal abnormalities, hypoglycemia and a predisposition (7% to 21%) to develop embryonic tumors in the first decade, with the highest risk before the age of 5 years . BWS is a heterogeneous syndrome and its molecular etiology is very complex because many mechanisms are involved. Most cases of BWS are sporadic, however, approximately 10% to 15% of BWS cases present positive family history in which autosomal dominant transmission with variable expressivity and incomplete penetrance is demonstrable. Several studies have reported the involvement of five principal genes distributed in two imprinting control regions (ICR1 and ICR2) at the critical 11p15 BWS region in both familial and sporadic BWS. Genetic and epigenetic alterations described in BWS include chromosomal abnormalities (translocations, inversion, and duplications), paternal uniparental disomy, hypo or hypermethylation at ICR1 and ICR2 and mutations in CDKN1C[2, 3]. Even though molecular studies are useful diagnostic tools for BWS, to date, all these findings only allow us to identify the molecular abnormalities involved in the 80% to 85% of patients with BWS, so a negative test cannot discard the BWS diagnosis which is still based on clinical criteria [4–8]. We report here on the novel association of BWS with 46,XX ovotesticular disorder found in a Mexican patient.
In our patient, the BWS diagnosis was based on the typical clinical findings as well as additional features such as wide neck, micro-clinodactyly of fourth and fifth fingers and toes, skin syndactyly, skin pigmentation abnormalities and 46,XX ovotesticular disorder. To the best of our knowledge, this is the first BWS patient found to have a coexisting ovotesticular disorder. Because gonadal differentiation involves a very complex genetic program at different embryonic stages, the occurrence of any disorder of sexual development (DSD) is a clinical challenge. The ovotesticular disorder is a rare DSD and the predominant karyotype (70% of cases) in these patients is 46,XX followed by chimerism XX/XY in about 20% . Testicular differentiation is accounted for by the presence of the master SRY gene in only 2% to 12% of cases, and remains unexplained in the remainder of cases. However, it has been suggested that mutations or deregulation of other genes involved in gonadal development in a 46,XX embryo can produce ambiguous genitalia [10, 11]. One marker of mammalian testis development is the size increase of rudimentary XY gonad, which is determined by the presence of SRY. The male-size increase is the result of coelomic cell proliferation after 24 hours of SRY gene expression, and originates in two stages. The first stage is the proliferation of SF1-positive cells, which will eventually give rise to the Sertoli cells. The second stage is the proliferation of SF1-negative cells. It has been postulated that this cell proliferation alters the transcriptional accessibility of the HOX gene clusters, thereby controlling the timing of the expression of specific genes and consequent cell differentiation . In the present patient we did not find any Y-chromosome sequences by FISH; however, we cannot rule out the possibility of a cryptic mutation or a small Y-bearing clone. Moreover, our patient also shares features with the Denys–Drash syndrome (Online Mendelian Inheritance in Man [OMIM] #194080) mapped in 11p13 whose distinctive features are Wilms’ tumor and a DSD similar to the 46,XX ovotesticular disorder. The implicated gene in Denys–Drash syndrome is WT1 which encodes for a zinc finger transcription factor that is expressed very early in the urogenital ridge and plays a crucial role in gonadal differentiation. A concurrent mutation in the WT1 gene may explain the DSD in our patient. Recent reports in mice indicate the imprinted genes network (IGN) regulates the gene expression through modulation of the imprinting pattern at different embryogenesis stages [13, 14]. For instance, the transcription factor ZAC1, one of the major IGN genes, especially modulates the expression of H19 and/or IGF2 genes. Accordingly, we speculate that in our patient a change in the methylation pattern of ZAC1 modifies the expression of H19 and/or IGF2 and gives rise to BWS phenotype, and perhaps even to the brachydactyly, because such a gene is highly expressed in chondrogenic tissue . Because ZAC1 also regulates SOX11, whose possible function is in gonadal development , the patient’s 46,XX ovotesticular disorder could result from an impaired IGN, although a random association cannot be excluded. In order to clarify the presence of these two complex pathologies (BWS and 46,XX ovotesticular disorder) in our patient is important to carry out future molecular analysis.
We report an unusual clinical presentation of BWS including a 46,XX ovotesticular disorder in a Mexican girl. Although a random association among these two conditions cannot be excluded, the coexistence of BWS and 46,XX ovotesticular disorder may lead to new insights in gonadal development. We speculate that a possible deregulation of the IGN has a fundamental role in the coexistence of these two disorders. To the best of our knowledge this is the first case where these two pathologies are coexisting.
Written informed consent was obtained from the patient’s legal guardian for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We acknowledge Dr Ramos-Solano Francisco (Histopathologist) for analyzing and interpreting histological data and providing pathology images.
- Smith AC, Choufani S, Ferreira JC, Weksberg R: Growth regulation, imprinted genes, and chromosome 11p15.5. Pediatr Res. 2007, 61 (5Pt 2): 43R-47R.View ArticlePubMedGoogle Scholar
- Diaz-Meyer N, Day CD, Khatod K, Maher ER, Cooper W, Reik W, Junien C, Graham G, Algar E, Der Kaloustian VM, Higgins MJ: Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet. 2003, 40: 797-801. 10.1136/jmg.40.11.797.View ArticlePubMedPubMed CentralGoogle Scholar
- Algar E, Dagar V, Sebaj M, Pachter N: An 11p15 imprinting center region 2 deletion in a family with Beckwith-Wiedemann syndrome provides insights into imprinting control at CDKN1C. PLoS One. 2011, 6: e29034-10.1371/journal.pone.0029034.View ArticlePubMedPubMed CentralGoogle Scholar
- Arima T, Kamikihara T, Hayashida T, Kato K, Inoue T, Shirayoshi Y, Oshimura M, Soejima H, Mukai T, Wake N: ZAC, LIT1 (KCNQ10T1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res. 2005, 33: 2650-2660. 10.1093/nar/gki555.View ArticlePubMedPubMed CentralGoogle Scholar
- Russo S, Finelli P, Recalcati MP, Ferraiuolo S, Cogliati F, Dalla Bernardina B, Tibiletti MG, Agosti M, Sala M, Bonati MT, Larizza L: Molecular and genomic characterisation of cryptic chromosomal alterations leading to paternal duplication of the 11p15.5 Beckwith-Wiedemann region. J Med Genet. 2006, 43: e39-10.1136/jmg.2005.038398.View ArticlePubMedPubMed CentralGoogle Scholar
- Elliot M, Maher ER: Beckwith-Wiedemann syndrome. J Med Genet. 1994, 31: 560-564. 10.1136/jmg.31.7.560.View ArticleGoogle Scholar
- Enklaar T, Zabel BU, Prawitt D: Beckwith-Wiedemann syndrome: multiple molecular mechanisms. Expert Rev Mol Med. 2006, 8: 1-19.View ArticlePubMedGoogle Scholar
- Weksberg R, Smith AC, Squire J, Sadowski P: Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet. 2003, 12: R61-R68. 10.1093/hmg/ddg067.View ArticlePubMedGoogle Scholar
- Kuhnle U, Krob G, Maier E: True hermaphroditism: presentation, management, outcome. Endocrinologist. 2003, 13: 214-218. 10.1097/01.ten.0000081681.43801.52.View ArticleGoogle Scholar
- Kousta E, Papathanasiou A, Skordis N: Sex determination and disorders of sex development according to the revised nomenclature and classification in 46, XX individuals. Hormones (Athens). 2010, 9: 218-131.View ArticleGoogle Scholar
- Ortenberg J, Oddoux C, Craver R, McElreavey K, Salas-Cortes L, Guillen-Navarro E, Ostrer H, Sarafoglou K, Clarke V, Yee H: SRY gene expression in the ovotestes of XX true hermaphrodites. J Urol. 2002, 167: 1828-1831. 10.1016/S0022-5347(05)65242-1.View ArticlePubMedGoogle Scholar
- Schamahl J, Eicher EM, Washburn LL, Capel B: SRY induce cell proliferation in the mouse gonad. Development. 2000, 127: 65-73.Google Scholar
- Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, Aknin C, Severac D, Chotard L, Kahli M, Le Digarcher A, Pavlidis P, Journot L: Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell. 2006, 11: 711-722. 10.1016/j.devcel.2006.09.003.View ArticlePubMedGoogle Scholar
- Gabory A, Ripoche MA, Le Digarcher A, Watrin F, Ziyyat A, Forné T, Jammes H, Ainscough JF, Surani MA, Journot L, Dandolo L: H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development. 2009, 136: 3413-3421. 10.1242/dev.036061.View ArticlePubMedGoogle Scholar
- Tsuda T, Markova D, Wang H, Evangelisti L, Pan TC, Chu ML: Zinc finger protein Zac1 is expressed in chondrogenic sites of the mouse. Dev Dyn. 2004, 229: 340-348. 10.1002/dvdy.10439.View ArticlePubMedGoogle Scholar
- Zhang L, Lin D, Zhang Y, Ma G, Zhang W: A homologue of Sox11 predominantly expressed in the ovary of the orange-spotted grouper Epinephelus coioides. Comp Biochem Physiol B Biochem Mol Biol. 2008, 149: 345-353. 10.1016/j.cbpb.2007.10.006.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.